Results 151 to 160 of about 7,760 (164)

Pharmacokinetics and pharmacodynamics of HAART

2004
The presently employed components of HAART are derived from a variety of chemically and pharmacologically different drug classes. The first compounds, which possessed antiretroviral activity were designed as nucleoside analogues in order to inhibit the reverse transcriptase. The first drug zidovudine (AZT) became available in 1987 and was followed soon
openaire   +2 more sources

HAART for Kids’ Hearts

Journal of the American College of Cardiology, 2017
Joseph W. Rossano, Kimberly Y. Lin
openaire   +2 more sources

Change of HAART

The Lancet, 1999
openaire   +2 more sources

Take HAART

Science, 2004
openaire   +2 more sources

Endocrinopathies in HIV, AIDS and HAART

Reviews in Endocrine and Metabolic Disorders, 2013
Amrit Bhangoo, Ninad Desai
openaire   +3 more sources

HAART versus heart

The Lancet Infectious Diseases, 2003
openaire   +2 more sources

HIV, the brain, children, HAART and ‘neuro-HAART’: a complex mix

AIDS, 2009
openaire   +2 more sources

HAART is dead, long live HAART plus interleukin-2

The Lancet, 1999
openaire   +2 more sources

Is HAART modifying the HIV epidemic?

The Lancet, 2010
Maggiolo, Franco, LEONE, SEBASTIANO
openaire   +3 more sources

HIV and HAART IN 1997

The Nurse Practitioner, 1997
Barbara D. Klaus, Michael J. Grodesky
openaire   +2 more sources